Most Favored Nation Pricing is Back – With a Vengeance
FDA Law Blog: Biosimilars
MAY 12, 2025
It sets forth three directives: HHS shall consider facilitating direct-to-consumer purchasing programs for pharmaceutical manufacturers that sell their products to American patients at the most-favored-nation (MFN) price. What types of drugs are to be covered: brands, generics, biologics, biosimilars, or some combination?
77 
Let's personalize your content